德国生物技术公司BioNTech SE(BNTX)今日盘中大涨5.1%,引发市场关注。据分析,该公司股价上涨或与其主营产品——新冠疫苗销售表现优异有关。
根据财报数据,BNTX第三季度实现营收约13.67亿美元,净利润2.18亿美元。作为全球抗疫工作中的重要一员,公司开发的mRNA新冠疫苗成为重要营收来源。随着疫情持续,mRNA疫苗需求有望持续上行,市场预期公司后续业绩表现良好。
此外,BNTX也在积极布局肿瘤免疫领域,打造全新的个性化免疫疗法产品线。依托在mRNA技术领域的领先优势,以及与多家制药巨头的合作关系,公司在研药物管线重点布局肿瘤等顽疾领域,前景广阔。在疫苗业务与肿瘤业务双轮驱动下,公司持续引领行业发展,符合投资者预期,推升股价上行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.